GH Research (GHRS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.23
- Estimate
- -$0.33
- Surprise
- +30.3%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
GH Research (GHRS) reported a narrower loss than forecast — diluted EPS of -$0.23 against the -$0.33 estimate (a 30.3% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates GHRS Sell at 5.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +30.3% surprise compares with a +7.7% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (1.6 < 4.0)
- Momentum score 2.5/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.33
- Price target
- $37.31
- Stop
- $26.35
- Upside to target
- +31.7%
- Reward-to-risk
- 3.0:1
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
GHRS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.94B
- P/E (fwd)
- -15.3
- 52-week range
- $11.83–$31.44
- Off 52-week high
- 9.9%
- RSI (14)
- 51
- Volume vs avg
- 0.41×
- Score today
- 5.5/10